Sun Pharmaceutical Industries shares are seen rising on unit Taro Pharmaceutical Industries price hikes.
Taro has pushed through price increase in a couple of products, says Credit Suisse.
The new set of price increases will boost EBITDA by 4 per cent, Credit Suisse analysts Anubhav Agarwal and Chunky Shah say.
Sun Pharma, not sated by Ranbaxy deal, may spend up to $7 billion on M&A, according to bankers.